BACELONA, SPAIN -- The Spanish biotech company AB-Biotics, traded on the Spanish Alternative Stock Market (MAB), and FB Health reached an agreement to launch the pharmacogenetic test Neurofarmagen® en Italy. FB Health, focused on neurology and founded by Dr. Francesco Bellini -founder of pharmaceutical companies such as BioChem-, has launched this month the analysis in the Italian market, where about 9 million people have suffered a mental disorder at least once in their lives. The company will present Neurofarmagen® in the National Congress of the Italian Society of Psychopathology (SOPSI) to be held next February in Milan.
Neurofarmagen®, developed by AB-Biotics, is a pharmacogenetic test which helps to identify the most appropriate psychiatric medication for each patient, by analyzing their DNA extracted from a saliva sample. A study including patients with depression, anxiety and psychotic disorders and bipolar disorders showed that the use of Neurofarmagen® reduces by almost 50% the rate of non-stabilized patients
Neurofarmagen® is currently available in Spain, marketed by AB-Biotics; in Brazil, by GlaxoSmithKline, and in Mexico, through Scienta Farma, and it is expected to be launched in other countries before the end of the year.
According to the European Study of Epidemiology of Mental Disorders (ESEMeD), 18.3% of Italian adults (about 9 million people) have suffered a mental disorder at least once in their lives, a percentage that reaches 24.4% for women. In addition, 7.3% of the adult population (3.6 million people) suffered a mental disorder in the past 12 months.
About AB-Biotics
AB-Biotics (ABB:SM) is a biotechnology company focused on research, development, protection and distribution of biotech unique solutions to improve the health and well-being of people. Its areas of activity include the development of pharmacogenetic tests for neuropsychiatry, and probiotics and other functional ingredients for the food and pharmaceutical industries. AB-Biotics is listed on the Spanish Alternative Investment Market (MAB). The company began in 2012 its international expansion and has closed several agreements for marketing their products in America, Europe and Asia. For additional information about AB-Biotics and its pipeline, please visit www.ab-biotics.com.
About FB Health
FB Health is a company focused on research, development and commercialization of innovative molecules for the prevention and treatment of diseases in the Neurologic and Geriatric field. It has developed business relationships with the best companies in the world to ensure steady progress, optimum safety, compliance and effectiveness of each molecule marketed. The President of FB Health, Mr. Francesco Bellini, has been engaged for over 30 years in the research of innovative solutions for human health. He founded BioChem Pharma and attracted the attention of the international pharmaceutical universe for the discovery of one of the earliest and most important antiviral drugs, Epivir. He’s also the founder of Neurochem, dedicated to neuroscience and particularly Alzheimer's disease.
Technology news on Global TechWire, reporting the business of life
sciences and innovation. Published by Innovative Public Relations, Inc.,
a Research Triangle, North Carolina based publicity and branding
consultancy. David Menzies, President. www.innovativepublicrelations.com.
